Qiao Ke

Qiao Ke

Auto-generated profile, based on publicly available information

Qiao Ke

Department of Hepatopancreatobiliary Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China, cas.cn

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
LWLei Wang
Lei Wang
MDManjun Deng
Manjun Deng
QKQiao Ke
Qiao Ke
JLJianying Lou
Jianying Lou
SZShuguo Zheng
Shuguo Zheng
YZYongyi Zeng
Yongyi Zeng
Background and Aims: The prognosis of intrahepatic cholangiocarcinoma (ICC) after radical resection is far from satisfactory; however, the clinical value of adjuvant therapy (AT) remains controversial. This multicenter study aimed to evaluate the clinical value of AT and identify potential patients who would be benefited from AT.Methods: Data from ICC patients who underwent radical resection were retrospectively collected from 12 hepatobiliary centers in China between December 2012 and December 2015. Patients were divided into AT and non‐AT groups based on whether AT was administered or not. Overall survival (OS) and disease‐free survival (DFS) were analyzed using the Kaplan‐Meier method before and after 1:2 propensity score matching (PSM). Subgroup analyses were conducted based on the established staging systems.Results: A total of 412 patients were enrolled in this study, and 77 patients (18.9%) received AT, including 32 (7.8%) patients who received transarterial chemoembolization (TACE), 21 (5.1%) patients who received chemotherapy, 10 (2.4%) patients who received radiotherapy, and 14 (3.4%) patients who received adjuvant chemoradiotherapy. The median OS and DFS were both longer in the AT group than in the non‐AT group (43.0 months vs 21.0 months, P = .015; 16.0 months vs 11.0 months, P = .045, respectively), and the advantage of AT was confirmed for both the OS and DFS (P = .023; P = .046, respectively) after 1:2 PSM. Furthermore, based on the established nomogram, only “middle‐risk” patients receiving AT cherished a longer median OS (43.0 months vs 20.0 months, P = .033). In subgroup analyses that were stratified by different AT strategies, patients receiving postoperative chemotherapy had a longer median OS (37.0 months vs 21.0 months, P = .039), while patients receiving postoperative TACE had a longer median DFS (50.0 months vs 11.0 months, P = .007).Conclusion: With the current data, we conclude that AT benefits ICC patients following radical resection, especially those “middle‐risk” patients, as evaluated by the established nomogram. However, exactly which patients are the most suitable for AT requires further study and validation.

22 August 2022 in Radiotherapy and Oncology
Verified
Journal Article
Open access
LWLei Wang
Lei Wang
LQLu Qiu
Lu Qiu
QKQiao Ke
Qiao Ke
HJHongbing Ji
Hongbing Ji
JWJunxin Wu
Junxin Wu
Recurrence remains the main bottleneck hindering outcomes of hepatectomy for hepatocellular carcinoma (HCC). Owing to technological advances, external beam radiotherapy (EBRT) is being increasingly used in the management of HCC; however, there is no consensus on the role of adjuvant EBRT following hepatectomy. A systematic review was conducted according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. PubMed, MedLine, Embase, the Cochrane Library, Web of Knowledge were used to screen eligible studies (published as of May 1st, 2022) that evaluated the clinical safety and efficacy of EBRT for HCC receiving hepatectomy. The endpoints were disease-free survival (DFS), overall survival (OS), and adverse events (AEs). A total of ten studies were eligible (three randomized controlled trials, one phase II trial, and six retrospective comparative studies). The pooled hazard ratio (HR) for median DFS and OS were both in favor of adjuvant EBRT compared with surgery alone (all P < 0.05), and the advantage of adjuvant EBRT was also confirmed in subgroups stratified by different populations (narrow margin, P < 0.05; microvascular invasion, P < 0.05; portal vein tumor thrombus, P < 0.05) and study designs (prospective studies, P < 0.05; retrospective studies, P < 0.05). Adjuvant EBRT was also found to be superior to adjuvant TACE (P < 0.05). Pooled rates of overall AEs and severe AEs were 65.3% and 12.2%, but no fatal AEs were reported. Adjuvant EBRT can be considered for HCC patients, especially those with a high risk of recurrence. Further studies are required for validation of these findings.

7 May 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
QKQiao Ke
Qiao Ke
YCYuqing Chen
Yuqing Chen
QHQizhen Huang
Qizhen Huang
NLNanping Lin
Nanping Lin
LWLei Wang
Lei Wang
JLJingfeng Liu
Jingfeng Liu
The incidence of a positive microscopic ductal margin (R1) after surgical resection for perihilar cholangiocarcinoma (pCCA) remains high, but the beneficial of additional resection has not been confirmed by any meta-analysis and randomized clinical trials (RCT), which also increased the risk of morbidity and mortality. Hence, a systematic review is warranted to evaluate the clinical value of additional resection of intraoperative R1 for pCCA. Eligible studies were searched by PubMed, MedLine, Embase, the Cochrane Library, Web of Science, from Jan.1st 2000 to Nov.30th 2019, evaluating the 1-, 3-, and 5-year overall survival (OS) rates of additional resection of intraoperative pathologic R1 for pCCA. Odds ratio (OR) with 95% confidence interval (CI) was used to determine the effect size by a randomized-effect model. Eight studies were enrolled in this meta-analysis, including 179 patients in the secondary R0 group, 843 patients in the primary R0 group and 253 patients in the R1 group. The pooled OR for the 1-, 3-, and 5-year OS rate between secondary R0 group and primary R0 group were 1.03(95%CI 0.64~1.67, P = 0.90), 0.92(95%CI 0.52~1.64, P = 0.78), and 0.83(95%CI 0.37~1.84, P = 0.65), respectively. The pooled OR for the 1-, 3-, and 5-year OS rate between secondary R0 group and R1 group were 2.14(95%CI 1.31~3.50, P = 0.002), 2.58(95%CI 1.28~5.21, P = 0.008), and 3.54(95%CI 1.67~7.50, P = 0.001), respectively. However, subgroup analysis of the West showed that the pooled OR for the 1-, and 3-year OS rate between secondary R0 group and R1 group were 2.05(95%CI 0.95~4.41, P = 0.07), 1.91(95%CI 0.96~3.81, P = 0.07), respectively. With the current data, additional resection should be recommended in selected patients with intraoperative R1, but the conclusion is needed further validation.

1 January 2026 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
XLXiao-Juan Lei
Xiao-Juan Lei
YJYu-Bing Jiao
Yu-Bing Jiao
XHXin-Hui Huang
Xin-Hui Huang
SLSheng-Zhao Li
Sheng-Zhao Li
QKQiao Ke
Qiao Ke
WGWu-Hua Guo
Wu-Hua Guo
Background: Spontaneous portosystemic shunts (SPSSs) frequently develop in individuals with cirrhosis. However, their clinical impact on the hepatic venous pressure gradient (HVPG) and liver function remains complex and a subject of ongoing debate. This retrospective study evaluated the relationship between SPSS diameter, particularly ultra‐large SPSS, and HVPG, liver dysfunction, and their predictive value in patients with cirrhosis. Methods: A retrospective study was conducted on 90 cirrhotic patients. The patients were categorized into three groups: no SPSS (none or φ < 3 mm), small SPSS (3 ≤ φ < 8 mm), and large SPSS ( φ ≥ 8 mm). The large SPSS group was further stratified into large (8 ≤ φ < 14.5 mm) and ultra‐large ( φ ≥ 14.5 mm) subgroups based on a receiver operating characteristic (ROC)−derived cutoff for hepatic encephalopathy (HE). Clinical parameters, HVPG, and vascular diameters were analyzed. Results: The large SPSS group had higher total bilirubin and a higher incidence of HE than the no SPSS group. Within the large SPSS cohort, the ultra‐large subgroup (≥ 14.5 mm) demonstrated significantly worse liver function (lower albumin, higher bilirubin, prolonged PT, increased INR, and poorer Child–Pugh/MELD scores), a higher proportion of Child–Pugh Class C, and elevated HVPG values (18.7 vs. 16.6 mmHg, p = 0.03) compared to the large subgroup. Critically, SPSS diameter showed a significant positive correlation with HVPG ( R = 0.314, p = 0.013). The incidence of HE was also significantly higher in the ultra‐large subgroup (55.52% vs. 11%, p = 0.001). Conclusions: The portal pressure‐lowering effect of SPSS does not correlate linearly with its diameter, exhibiting a threshold‐dependent attenuation as shunt size exceeds 14.5 mm. This cutoff may serve as a predictor of increased risk for HE and liver dysfunction in cirrhosis, supporting its potential role in clinical risk stratification and decision‐making for cirrhosis patients with SPSS.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JZJian-Feng Zheng
Jian-Feng Zheng
XJXiao-He Jiang
Xiao-He Jiang
YCYu Chen
Yu Chen
LCLi-Li Cai
Li-Li Cai
XWXiao-Zhong Wang
Xiao-Zhong Wang
JZJi-Xiang Zhang
Ji-Xiang Zhang
E15587 Background: Eukaryotic initiation factor was reported to be dysregulated in human cancers. However, how it is potentially oncogenic remains elusive. Here we investigate the role of eukaryotic initiation factor 3B in the pathogenesis of hepatocellular carcinoma. Methods: Eukaryotic initiation factor 3B expression in hepatocellular carcinoma lesions and the cancer cell lines was measured by quantitative real-time polymerase chain reaction and immunohistochemistry analyses. Lentivirus-mediated RNA inference was utilized to silence Eukaryotic initiation factor 3B expression in SMMC-71cells, thereafter, cell proliferation, cell colony formation, and cell cycle phase distribution were examined. Eukaryotic initiation factor 3B-silenced hepatocellular carcinoma cells were implanted into nude mice to examine tumor biobehavior in vivo. Microarray gene expression analysis and Western blotting validation were used to determine global gene expression following eukaryotic initiation factor 3B silencing. Results: A significant overexpression of eukaryotic initiation factor 3B was found in hepatocellular carcinoma lesions compared to the matching adjacent non-tumor tissues. High expression of eukaryotic initiation factor 3B was significantly correlated with advanced tumor-node-metastasis stage and poor survival rates. Knockdown of eukaryotic initiation factor 3B significantly decreased proliferation and clonability of tumor cells in vitro and inhibited tumor growth in vivo; Eukaryotic initiation factor 3B silencing markedly downregulated expressions of epithelial growth factor receptor and zipper sterile-α-motif kinase. Conclusions: up-regulated Eukaryotic initiation factor 3B is associated with malignant transformation in hepatocellular carcinoma, and may contribute to hepatocarcinogenesis via targeting EGFR and ZAK, which could serve as a novel therapeutic target for hepatocellular carcinoma.

3 November 2022 in Research Square
Verified
Preprint
Open access
PDF file
QKQiao Ke
Qiao Ke
XYXueping Yu
Xueping Yu
XWXuan Wang
Xuan Wang
JHJinfa Huang
Jinfa Huang
BLBiding Lin
Biding Lin
WGWuhua Guo
Wuhua Guo
Background and aim Patients with cirrhosis have a high prevalence of spontaneous portosystemic shunt (SPSS), but it remains controversial whether the presence of SPSS is associated with liver function and portal hypertension (PHT)-related complications. In this study, we aimed to investigate the prevalence, clinical characteristics and related factors of SPSS in cirrhotic patients. Methods Patients who were diagnosed with hepatitis B-related cirrhosis between Jan 2020 and Oct 2021 were retrospectively recruited from five centers in China. All eligible patients were classified into SPSS and non-SPSS groups and their clinical characteristics were compared. Logistic regression analyses were performed to identify clinical characteristics associated with SPSS, and then to assess the independent impact of SPSS on the risk of PHT-related complications. Results Of the 1282 patients included in this study, SPSS was identified in 488 patients (38.1%). SPSS group had a higher proportion of patients with hepatofugal flow in portal vein, thinner diameter of right branch of portal vein (RPV), thicker diameter of left branch of portal vein (LPV), splenic vein (SV) and superior mesenteric vein (SMV), more severe liver function impairment, higher incidence and severity of esophageal and gastric varices (EGV), and a higher prevalence of PHT-related complications [EGV bleeding (EGVB), portal vein thrombosis (PVT), hepatic encephalopathy (HE), ascites, and hepatocellular carcinoma (HCC)] (all P < 0.05). On multivariable logistic regression analyses, MELD score, diameter of RPV and SV, hepatofugal flow in portal vein, EV or GV or EGV on radiological evaluation, presence of EGVB, PVT, HE, and moderate–severe ascites were independently associated with SPSS (all P < 0.05). In addition, presence of SPSS was identified as an independent risk factor for EGVB, PVT and HE (all P < 0.05). Conclusion SPSS may indicate severe liver damage and a high risk of PHT-related complications.